

2016年度 第3四半期決算 補足資料 Additional Information for the Third Quarter of FY2016

(百万円: millions of yen)

セグメント別売上概況 Net Sales by Business Segment

%=前年同期比/ YoY

		Q3YTD FY2015			Q3YTD FY2016					
		JPN	Overseas	WW	JPN	%	Overseas	%	WW	%
TIS	Interventional Systems	27,263	105,434	132,698	26,371	-3.3%	102,282	-3.0%	128,654	-3.0%
ニューロバスキュラー	Neurovascular	1,756	17,402	19,158	2,100	19.6%	17,558	0.9%	19,659	2.6%
CV	Cardiovascular Systems	7,238	23,897	31,135	7,435	2.7%	21,546	-9.8%	28,982	-6.9%
血管	Vascular Graft	1,507	8,741	10,249	1,438	-4.6%	7,837	-10.3%	9,275	-9.5%
心臓血管カンパニー	Cardiac and Vascular Company	37,765	155,476	193,241	37,345	-1.1%	149,225	-4.0%	186,570	-3.5%
基盤医療器	General Hospital Products	37,279	21,411	58,691	38,178	2.4%	19,023	-11.2%	57,201	-2.5%
D&D	Drug & Device	41,012	4,047	45,059	39,456	-3.8%	3,912	-3.3%	43,368	-3.8%
DM・ヘルスケア	DM and Consumer Healthcare	15,965	3,060	19,026	15,880	-0.5%	2,528	-17.4%	18,408	-3.2%
ホスピタルカンパニー	General Hospital Company	94,257	28,520	122,777	93,515	-0.8%	25,464	-10.7%	118,979	-3.1%
血液システムカンパニー	Blood Management Company	8,410	71,561	79,972	8,577	2.0%	60,114	-16.0%	68,692	-14.1%
その他	Others	-	-	-	152	-	-	-	152	-
計	Total	140,433	255,558	395,991	139,591	-0.6%	234,803	-8.1%	374,394	-5.5%

(期中平均為替レート)

Average exchange rates

(USD1=¥121.74)

(EUR1=¥134.41)

(USD1=¥106.60)

(EUR1=¥117.98)

四半期別推移 Quarterly History for the Income Statement

		Q1	Q2	Q3	Q4	FY2015	Q1	Q2	Q3	FY2016
		FY2015	FY2015	FY2015	FY2015	FY2015	FY2016	FY2016	FY2016	Forecast
売上高	Net Sales	128,660	130,506	136,824	129,034	525,026	124,519	120,590	129,284	510,000
	各四半期売上高/年間売上高	24.5%	24.9%	26.0%	24.6%	100.0%	24.4%	23.6%	25.3%	100.0%
売上総利益	Gross Profit	69,047	70,310	75,290	70,252	284,900	69,726	66,282	69,274	
	%Net Sale	53.7%	53.9%	55.0%	54.4%	54.3%	56.0%	55.0%	53.6%	
販売管理費	SG&A Expenses	49,598	50,657	50,276	52,664	203,197	48,370	48,267	49,741	
	%Net Sale	38.6%	38.8%	36.7%	40.8%	38.7%	38.8%	40.0%	38.5%	
営業利益	Operating Income	19,449	19,652	25,013	17,587	81,703	21,356	18,014	19,533	71,000
	%Net Sale	15.1%	15.1%	18.3%	13.6%	15.6%	17.2%	14.9%	15.1%	13.9%
経常利益	Ordinary Income	20,592	15,166	25,218	12,113	73,090	15,123	15,478	21,602	62,000
	%Net Sale	16.0%	11.6%	18.4%	9.4%	13.9%	12.1%	12.8%	16.7%	12.2%
当期純利益	Net Income	14,504	12,508	16,471	7,191	50,676	10,110	10,312	11,399	47,500
	%Net Sale	11.3%	9.6%	12.0%	5.6%	9.7%	8.1%	8.6%	8.8%	9.3%

キャッシュ・フロー計算書 (要約) Statements of Cash Flows

参考情報 Additional Information

		Q3YTD	Q3YTD
		FY2015	FY2016
営業キャッシュ・フロー	Net Cash Provided by (Used in) Operating Activities	51,641	53,884
投資キャッシュ・フロー	Net Cash Provided by (Used in) Investing Activities	Δ 13,920	Δ 51,394
フリーキャッシュ・フロー	Free Cash Flow	37,721	2,489
財務キャッシュ・フロー	Net Cash Provided by (Used in) Financing Activities	Δ 24,539	112,690
現金及び現金同等物の換算差額	Effect of exchange rate change on cash and cash equivalents	Δ 1,308	332
現金及び現金同等物の増減	Net increase (decrease) in cash and cash equivalents	11,872	115,512
現金及び現金同等物の期首残高	Cash and cash equivalents at beginning of period	176,662	146,927
現金及び現金同等物の四半期末残高	Cash and cash equivalents at end of period	188,534	262,439

		Q3YTD	Q3YTD	FY2016
		FY2015	FY2016	Forecast
研究開発費	Research and Development	23,261	24,519	35,500
設備投資額	Capital Expenditure	21,260	24,776	35,000
減価償却費	Depreciation and Amortization	33,228	32,428	44,000